Zhejiang Huahai Pharmaceutical Co Ltd (600521) - Total Liabilities
Based on the latest financial reports, Zhejiang Huahai Pharmaceutical Co Ltd (600521) has total liabilities worth CN¥12.36 Billion CNY (≈ $1.81 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Zhejiang Huahai Pharmaceutical Co Ltd (600521) long-term investment share to see how much of total assets are deployed in long-term investments.
Zhejiang Huahai Pharmaceutical Co Ltd - Total Liabilities Trend (2000–2025)
This chart illustrates how Zhejiang Huahai Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 600521 asset base.
Zhejiang Huahai Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Huahai Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fielmann Aktiengesellschaft
XETRA:FIE
|
Germany | €1.42 Billion |
|
Shaanxi Sirui Advanced Materials Co. Ltd. A
SHG:688102
|
China | CN¥1.48 Billion |
|
PTT OIL+RET.BUS.-NVDR- 10
F:7F80
|
Germany | €120.04 Billion |
|
Palomar Holdings Inc
NASDAQ:PLMR
|
USA | $2.07 Billion |
|
Cal-Maine Foods Inc
NASDAQ:CALM
|
USA | $467.04 Million |
|
Hoegh Autoliners ASA
OL:HAUTO
|
Norway | Nkr1.06 Billion |
|
Uni-President China Holdings Ltd
F:58U
|
Germany | €10.89 Billion |
|
AXIA Energia
NYSE:AXIA
|
USA | $157.16 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Zhejiang Huahai Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Zhejiang Huahai Pharmaceutical Co Ltd (600521) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Huahai Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Huahai Pharmaceutical Co Ltd (2000–2025)
The table below shows the annual total liabilities of Zhejiang Huahai Pharmaceutical Co Ltd from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥12.05 Billion ≈ $1.76 Billion |
+7.17% |
| 2024-12-31 | CN¥11.24 Billion ≈ $1.64 Billion |
+8.62% |
| 2023-12-31 | CN¥10.35 Billion ≈ $1.51 Billion |
-0.55% |
| 2022-12-31 | CN¥10.41 Billion ≈ $1.52 Billion |
+19.72% |
| 2021-12-31 | CN¥8.69 Billion ≈ $1.27 Billion |
+38.70% |
| 2020-12-31 | CN¥6.27 Billion ≈ $917.01 Million |
+26.58% |
| 2019-12-31 | CN¥4.95 Billion ≈ $724.43 Million |
-19.64% |
| 2018-12-31 | CN¥6.16 Billion ≈ $901.51 Million |
+91.80% |
| 2017-12-31 | CN¥3.21 Billion ≈ $470.03 Million |
+49.50% |
| 2016-12-31 | CN¥2.15 Billion ≈ $314.40 Million |
+19.69% |
| 2015-12-31 | CN¥1.80 Billion ≈ $262.69 Million |
+44.31% |
| 2014-12-31 | CN¥1.24 Billion ≈ $182.03 Million |
-14.02% |
| 2013-12-31 | CN¥1.45 Billion ≈ $211.71 Million |
+14.14% |
| 2012-12-31 | CN¥1.27 Billion ≈ $185.49 Million |
+21.01% |
| 2011-12-31 | CN¥1.05 Billion ≈ $153.28 Million |
+42.33% |
| 2010-12-31 | CN¥735.92 Million ≈ $107.69 Million |
+40.72% |
| 2009-12-31 | CN¥522.98 Million ≈ $76.53 Million |
+26.17% |
| 2008-12-31 | CN¥414.51 Million ≈ $60.66 Million |
+44.04% |
| 2007-12-31 | CN¥287.78 Million ≈ $42.11 Million |
+29.25% |
| 2006-12-31 | CN¥222.66 Million ≈ $32.58 Million |
+28.92% |
| 2005-12-31 | CN¥172.70 Million ≈ $25.27 Million |
+56.97% |
| 2004-12-31 | CN¥110.03 Million ≈ $16.10 Million |
+23.25% |
| 2003-12-31 | CN¥89.27 Million ≈ $13.06 Million |
-46.75% |
| 2002-12-31 | CN¥167.62 Million ≈ $24.53 Million |
+10.48% |
| 2001-12-31 | CN¥151.72 Million ≈ $22.20 Million |
+34.52% |
| 2000-12-31 | CN¥112.79 Million ≈ $16.50 Million |
-- |
About Zhejiang Huahai Pharmaceutical Co Ltd
Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production, and sales of generic drugs, biologics, drugs, and specialty active pharmaceutical ingredients in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging componen… Read more